IMGN News and Press, ImmunoGen Inc. From 05/10/21

ImmunoGen, Inc. (IMGN) Q1 2021 Earnings Conference Call May 10, 2021, 08:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications and IR Mark Enyedy - President and CEO Anna Berkenblit - CMO Susan Altschuller - CFO Conference Call Participants John Newman - C...

Image source: The Motley Fool. Immunogen Inc (NASDAQ: IMGN) Q1 2021 Earnings Call May 10, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Immunogen Inc (IMGN) Q1 2021 Earnings Call Transcript

ImmunoGen (IMGN) shares fall nearly 2% during premarket trading after reporting first-quarter revenue that missed Wall Street estimates, and re-affirmed its financial guidance for the year.The company's net revenue during the quarter increased 18% to $15.7M, but missed analysts...

ImmunoGen (IMGN): Q1 GAAP EPS of -$0.17 beats by $0.02.Revenue of $15.7M (+18.1% Y/Y) misses by $1.82M.For 2021, ImmunoGen guidance remains unchanged: Revenues between $65M and $75M vs. consensus of $70.70M; operating expenses between $200M and $210M; and cash and cash equivalents a...

Top-Line Data from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer Expected in the Fourth Quarter of 2021 FORWARD II Mirvetuximab Plus Avastin ® Doublet Cohort in Recurrent Ovarian Cancer, Regardless of Platinum Status, Selected for Oral Presentati...

Riding powerful fundamental improvement, ImmunoGen has made strong turnaround progress. With the upcoming data release for SORAYA and MIRASOL, you can expect ImmunoGen to break the bearish trend to trade higher. This turnaround stock will likely reward you with substantial upside ...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, May 10, 2021 to discuss its first quarter operating results. Managem...

First-in-Class ADAM9-Targeting ADC Demonstrates Anti-Tumor Activity in Multiple Solid Tumor Models ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that a poster highlighting pr...

IMGN has had a mixed history of trial failures and some successes with licensing deals. However, it looks likely that at least one of two drugs will get approved by 2022. Their licensing revenue stream also adds to my interest. For further details see: ImmunoGen: Major C...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upco...